Closed Loop Medicine Demonstrates Application of Novel Drug Plus Software Product for Personalized Treatment of Hypertension
Retrieved on:
torsdag, februari 8, 2024
Medical Devices, Health, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Innovation, American College, Senior, Orthostatic hypertension, Medicine, Invention, Death, Amlodipine, Therapy, Disease, Drug intolerance, Patient, Cerebral edema, COVID, Triage, Trust, Hypertension, BP, Journal, American Heart Association, Journal of Human Hypertension, JAHA, Innovate UK, Blood pressure, Pharmaceutical industry
Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).
Key Points:
- Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).
- Hypertension is the leading preventable cause of morbidity and premature death worldwide.
- High adherence rates were reported (both app usage and medication) and patient retention was exceptionally high with no discontinuations due to drug intolerance.
- Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension.